Go to content

In The News

CAR-T cell therapies going in vivo

Read about CAR-T cell therapies going in vivo

Inside Acuitas Therapeutics: The Vancouver Life Science Lab Powering Medical Breakthroughs

Acuitas Therapeutics shelled out an undisclosed sum to acquire a majority stake in Montreal-based and privately held RNA Technologies & Therapeutics.

Read about Inside Acuitas Therapeutics: The Vancouver Life Science Lab Powering Medical Breakthroughs

Why Does the Future of Genetic Medicines Rely on LNP Targeting Strategies? Read What Experts Have to Say

Active targeting via site-specific ligand attachment, including DARPin conjugation, enables high-affinity cell recognition and has shown ~90% mRNA expression in human CD8⁺ T cells, supporting in-vivo CAR-T concepts.

Read about Why Does the Future of Genetic Medicines Rely on LNP Targeting Strategies? Read What Experts Have to Say

Optimising potency and delivery: the new frontier of LNP in mRNA cancer vaccines

Optimising potency and delivery: the new frontier of LNP in mRNA cancer vaccines.

Read about Optimising potency and delivery: the new frontier of LNP in mRNA cancer vaccines

Biotech Firms Cement a Longstanding Collaboration via Strategic Investment

Read about Biotech Firms Cement a Longstanding Collaboration via Strategic Investment

Acuitas Therapeutics Buys Majority Stake In RNA Technologies & Therapeutics

Read about Acuitas Therapeutics Buys Majority Stake In RNA Technologies & Therapeutics

Acuitas Takes Majority stake in Montreal-based RNA Construct Manufacturer

Acuitas Therapeutics shelled out an undisclosed sum to acquire a majority stake in Montreal-based and privately held RNA Technologies & Therapeutics.

Read about Acuitas Takes Majority stake in Montreal-based RNA Construct Manufacturer

Acuitas Therapeutics: Interview With President & CEO Dr. Thomas Madden About The Biotech Company

Read about Acuitas Therapeutics: Interview With President & CEO Dr. Thomas Madden About The Biotech Company

A Year of Firsts: Personalized Gene Editing Comes of Age

Read about A Year of Firsts: Personalized Gene Editing Comes of Age

Seven Biopharma Trends to Watch in 2026

Read about Seven Biopharma Trends to Watch in 2026